Dar Aldawa has obtained an industrial investment license for the establishment of a pharmaceutical plant in the Kingdom of Saudi Arabia

Dar Aldawa has taken a significant step toward its vision for regional expansion by securing an investment license from the Ministry of Investment in the Kingdom of Saudi Arabia. This milestone marks the beginning of preparations for establishing a cutting-edge pharmaceutical factory in the Kingdom.

This new facility is set to enhance Dar Aldawa existing production capabilities, complementing its advanced research centers and production lines in Jordan and Algeria. The move underscores the company’s commitment to addressing the growing healthcare needs in the region while maintaining its position as a leader in the pharmaceutical industry.

Dr. Akram Jarrab, Chairman of the Board of Directors, emphasized: “This achievement reflects our dedication to producing innovative pharmaceutical solutions. We are committed to delivering high-quality healthcare products and expertise to the Saudi market, benefiting patients and caregivers alike.”

CEO Khaled Harb added: “This is a proud moment for Dar Aldawa, as it reinforces our strong presence in the Saudi market, one of the most strategic in the region.